GoldenGolden
Advanced Search
Akero Therapeutics

Akero Therapeutics

Akero Therapeutics is a Cambridge, Massachusetts-based biotechnology company focused on reversing the NASH epidemic by restoring the body's metabolism to a balanced state.

Akero Therapeutics is a biotechnology company. Akero's mission is to reverse the course of serious metabolic diseases and change patients’ lives. The company's dedicated team is laser-focused on reversing the NASH epidemic by restoring the metabolism of the body to a balanced state.

Its multi-modal drug, efruxifermin (EFX), mimics FGF21 to face the many facets of NASH, and clinical data suggests that it possesses the potential to become a foundational NASH monotherapy.

Akero is involved in R&D which is solely focused on developing medicines to reverse the escalating NASH epidemic, a disease that involves the whole body, and requires treatment of the imbalanced metabolism. This R&D approach is applied to address the underlying metabolic causes and the downstream pathological pathways leading to liver cirrhosis, liver failure and death.

Timeline

December 12, 2018
Akero Therapeutics raises a $70,000,000 series B round from Atlas Venture, Biotechnology Value Fund, Boxer Capital, Cormorant Asset Management, Janus Henderson Investors, LifeSci Venture Partners, Redmile Group, Rock Springs Capital, Versant Ventures and venBio Partners.
June 25, 2018
Akero Therapeutics raises a $65,000,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 26, 2021
BioSpace
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Yuan Xu, Ph.D., to its board of directors as an independent director.
Akero Therapeutics
February 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Disc Medicine
January 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating...
BioSpace
June 10, 2020
BioSpace
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced the appointment of Tom Heyman to its board of directors as an independent directo

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.